Reporter phage and breath tests: Emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy

Paras Jain, David S. Thaler, Mamoudou Maiga, Graham S. Timmins, William R. Bishai, Graham F. Hatfull, Michelle H. Larsen, William R. Jacobs

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The rapid and accurate diagnosis of active tuberculosis (TB) and its drug susceptibility remain a challenge. Phenotypic assays allow determination of antibiotic susceptibilities even if sequence data are not available or informative. We review 2 emerging diagnostic approaches, reporter phage and breath tests, both of which assay mycobacterial metabolism. The reporter phage signal, Green fluorescent protein (GFP) or β-galactosidase, indicates transcription and translation inside the recipient bacilli and its attenuation by antibiotics.Different breath tests assay, (1) exhaled antigen 85, (2) mycobacterial urease activity, and (3) detection by trained rats of diseasespecific odor in sputum, have also been developed. When compared with culture, reporter phage assays shorten the time for initial diagnosis of drug susceptibility by several days. Both reporter phage and breath tests have promise as early markers to determine the efficacy of treatment. While sputum often remains smear and Mycobacterium tuberculosis DNA positive early in the course of efficacious antituberculous treatment, we predict that both breath and phage tests will rapidly become negative. If this hypothesis proves correct, phage assays and breath tests could become important surrogate markers in early bactericidal activity (EBA) studies of new antibiotics.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume204
Issue numberSUPPL. 4
DOIs
StatePublished - Nov 15 2011

Fingerprint

Breath Tests
Microbial Drug Resistance
Bacteriophages
Tuberculosis
Anti-Bacterial Agents
Sputum
Galactosidases
Urease
Green Fluorescent Proteins
Mycobacterium tuberculosis
Pharmaceutical Preparations
Bacillus
Biomarkers
Antigens
DNA

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Reporter phage and breath tests : Emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy. / Jain, Paras; Thaler, David S.; Maiga, Mamoudou; Timmins, Graham S.; Bishai, William R.; Hatfull, Graham F.; Larsen, Michelle H.; Jacobs, William R.

In: Journal of Infectious Diseases, Vol. 204, No. SUPPL. 4, 15.11.2011.

Research output: Contribution to journalArticle

Jain, Paras ; Thaler, David S. ; Maiga, Mamoudou ; Timmins, Graham S. ; Bishai, William R. ; Hatfull, Graham F. ; Larsen, Michelle H. ; Jacobs, William R. / Reporter phage and breath tests : Emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. SUPPL. 4.
@article{659945f9952a461c83f3d4d7f5094a39,
title = "Reporter phage and breath tests: Emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy",
abstract = "The rapid and accurate diagnosis of active tuberculosis (TB) and its drug susceptibility remain a challenge. Phenotypic assays allow determination of antibiotic susceptibilities even if sequence data are not available or informative. We review 2 emerging diagnostic approaches, reporter phage and breath tests, both of which assay mycobacterial metabolism. The reporter phage signal, Green fluorescent protein (GFP) or β-galactosidase, indicates transcription and translation inside the recipient bacilli and its attenuation by antibiotics.Different breath tests assay, (1) exhaled antigen 85, (2) mycobacterial urease activity, and (3) detection by trained rats of diseasespecific odor in sputum, have also been developed. When compared with culture, reporter phage assays shorten the time for initial diagnosis of drug susceptibility by several days. Both reporter phage and breath tests have promise as early markers to determine the efficacy of treatment. While sputum often remains smear and Mycobacterium tuberculosis DNA positive early in the course of efficacious antituberculous treatment, we predict that both breath and phage tests will rapidly become negative. If this hypothesis proves correct, phage assays and breath tests could become important surrogate markers in early bactericidal activity (EBA) studies of new antibiotics.",
author = "Paras Jain and Thaler, {David S.} and Mamoudou Maiga and Timmins, {Graham S.} and Bishai, {William R.} and Hatfull, {Graham F.} and Larsen, {Michelle H.} and Jacobs, {William R.}",
year = "2011",
month = "11",
day = "15",
doi = "10.1093/infdis/jir454",
language = "English (US)",
volume = "204",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Reporter phage and breath tests

T2 - Emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy

AU - Jain, Paras

AU - Thaler, David S.

AU - Maiga, Mamoudou

AU - Timmins, Graham S.

AU - Bishai, William R.

AU - Hatfull, Graham F.

AU - Larsen, Michelle H.

AU - Jacobs, William R.

PY - 2011/11/15

Y1 - 2011/11/15

N2 - The rapid and accurate diagnosis of active tuberculosis (TB) and its drug susceptibility remain a challenge. Phenotypic assays allow determination of antibiotic susceptibilities even if sequence data are not available or informative. We review 2 emerging diagnostic approaches, reporter phage and breath tests, both of which assay mycobacterial metabolism. The reporter phage signal, Green fluorescent protein (GFP) or β-galactosidase, indicates transcription and translation inside the recipient bacilli and its attenuation by antibiotics.Different breath tests assay, (1) exhaled antigen 85, (2) mycobacterial urease activity, and (3) detection by trained rats of diseasespecific odor in sputum, have also been developed. When compared with culture, reporter phage assays shorten the time for initial diagnosis of drug susceptibility by several days. Both reporter phage and breath tests have promise as early markers to determine the efficacy of treatment. While sputum often remains smear and Mycobacterium tuberculosis DNA positive early in the course of efficacious antituberculous treatment, we predict that both breath and phage tests will rapidly become negative. If this hypothesis proves correct, phage assays and breath tests could become important surrogate markers in early bactericidal activity (EBA) studies of new antibiotics.

AB - The rapid and accurate diagnosis of active tuberculosis (TB) and its drug susceptibility remain a challenge. Phenotypic assays allow determination of antibiotic susceptibilities even if sequence data are not available or informative. We review 2 emerging diagnostic approaches, reporter phage and breath tests, both of which assay mycobacterial metabolism. The reporter phage signal, Green fluorescent protein (GFP) or β-galactosidase, indicates transcription and translation inside the recipient bacilli and its attenuation by antibiotics.Different breath tests assay, (1) exhaled antigen 85, (2) mycobacterial urease activity, and (3) detection by trained rats of diseasespecific odor in sputum, have also been developed. When compared with culture, reporter phage assays shorten the time for initial diagnosis of drug susceptibility by several days. Both reporter phage and breath tests have promise as early markers to determine the efficacy of treatment. While sputum often remains smear and Mycobacterium tuberculosis DNA positive early in the course of efficacious antituberculous treatment, we predict that both breath and phage tests will rapidly become negative. If this hypothesis proves correct, phage assays and breath tests could become important surrogate markers in early bactericidal activity (EBA) studies of new antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=80054735136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054735136&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir454

DO - 10.1093/infdis/jir454

M3 - Article

C2 - 21996696

AN - SCOPUS:80054735136

VL - 204

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 4

ER -